The search for effective drugs to treat pre-eclampsia remains ongoing,
yet developing new treatments for obstetric conditions poses significant
challenges. Drug repurposing emerges as a viable alternative to these
challenges. Notably, metformin, a complex I inhibitor, has recently
demonstrated potential in addressing pre-eclampsia. Through a
comprehensive literature review, pyrvinium was identified as the sole
complex I inhibitor deemed safe during pregnancy that has yet to be
explored for pre-eclampsia treatment. This paper presents a compelling
case for conducting mechanistic and efficacy studies on pyrvinium,
leveraging its robust pharmacological attributes and proven safety
record.